11.67
0.32 (2.82%)
| Previous Close | 11.35 |
| Open | 11.40 |
| Volume | 120,997 |
| Avg. Volume (3M) | 92,518 |
| Market Cap | 1,001,546,304 |
| Price / Sales | 8.43 |
| Price / Book | 14.02 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2025 - 28 Mar 2025 |
| Profit Margin | -84.57% |
| Operating Margin (TTM) | 16.61% |
| Diluted EPS (TTM) | -1.04 |
| Quarterly Revenue Growth (YOY) | -20.50% |
| Quarterly Earnings Growth (YOY) | -71.70% |
| Total Debt/Equity (MRQ) | 1.82% |
| Current Ratio (MRQ) | 3.72 |
| Operating Cash Flow (TTM) | 2.48 M |
| Levered Free Cash Flow (TTM) | 8.44 M |
| Return on Assets (TTM) | 10.18% |
| Return on Equity (TTM) | -85.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Gyre Therapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | -5.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | -1.40 |
|
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 74.63% |
| % Held by Institutions | 1.96% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MA SONGJIANG | - | 11.31 | -6,000 | -67,860 |
| Aggregate Net Quantity | -6,000 | |||
| Aggregate Net Value ($) | -67,860 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 11.31 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MA SONGJIANG | Officer | 04 Mar 2025 | Automatic sell (-) | 2,000 | 10.90 | 21,800 |
| MA SONGJIANG | Officer | 03 Mar 2025 | Automatic sell (-) | 2,000 | 11.43 | 22,860 |
| MA SONGJIANG | Officer | 28 Feb 2025 | Automatic sell (-) | 2,000 | 11.60 | 23,200 |
| Date | Type | Details |
|---|---|---|
| 06 Jan 2025 | Announcement | Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors |
| 3Y Average Dividend Yield | 6.31% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 13 Jan 2023 | 26 Dec 2022 | 12 Jan 2023 | 0.24 Cash |
| 21 Sep 2022 | 24 Aug 2022 | 20 Sep 2022 | 1.43 Cash |
| 20 Aug 2015 | 04 Aug 2015 | 19 Aug 2015 | 1.6492 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2023 | 0.240 | 1 | 0.93 |
| 2022 | 1.43 | 1 | 17.99 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |